Subscription Required

Only paid subscribers* to Drug Benefit News can access this Web portal with three years of back issues, searchable article archives and other valuable resources.

Subscribers to Drug Benefit News receive

  • 24 biweekly issues (8 pages) of timely news and insightful strategies for reducing costs and improving outcomes, delivered First Class by U.S. Mail and electronically
  • Special E-Alerts when timely news breaks
  • Access to your subscriber-only web page with:
    • A posting of the latest issue
    • Searchable archives of all articles for the past three years
    • A chronological posting of back issues for three years
  • Recent stories of interest and hot topic articles grouped for convenient reading and regular postings from your editor
View a sample and get more information
April 18, 2014

Recent Stories of Interest

From Drug Benefit News - New annual trend reports from CVS Caremark Corp. and Express Scripts Holding Co. point to double-digit increases in spending on specialty medications as a major contributor to overall drug trend in 2013, but specialty wasn’t the only factor to blame. Both companies advise plan sponsors to watch for continuing price inflation — not just on brand and specialty drugs but also on generics — as well as waning generic opportunities, steadily rising utilization and new specialty drug approvals as trend drivers in 2014 and beyond. Read more

While the February draft of CMS’s 2015 Advance Notice and Call Letter… Read more

When it comes to curbing the use of manufacturer-offered copay coupons and… Read more

A new report from a coalition of stakeholders suggests that a considerable… Read more

From the Editor

Welcome to your Drug Benefit News subscriber-only Web page

Be sure to visit often, for PDFs of issues, archives of articles and data, and more!

Please e-mail me with comments on the last issue of Drug Benefit News, story ideas for future issues or any other suggestions you have that can make the newsletter more useful for you.

April 22, 2014
GlaxoSmithKline Deal With Novartis Includes Building Up OTC Business While Divesting Oncology Portfolio

New GlaxoSmithKline three-part deal with Novartis includes building up OTC business while divesting oncology portfolio. http://tinyurl.com/lolstrc

April 22, 2014
FDA Approves Lilly Stomach Cancer Drug

FDA approves Eli Lilly’s Cyramza (ramucirumab) to treat advanced gastric cancer after prior chemo; the FDA gave the injectable orphan drug status and approved it under its priority review program http://tinyurl.com/kut2oru

April 22, 2014
FDA Approves Lilly Stomach Cancer Drug

FDA approves Eli Lilly’s Cyramza (ramucirumab) to treat advanced gastric cancer after prior chemo; the FDA gave the injectable orphan drug status and approved it under its priority review program http://tinyurl.com/kut2oru

Updated Regularly

Featured Hot Topics

Search for your own Hot Topics

It's quick and easy to sign up for FREE access to AISHealth.com!

Why do I need to register?